Want to see AU:IMU full AI Analyst Report?
Top Page
Imugene
(Sydney:IMU)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.03
▼(-51.43% Downside)
Action:Reiterated
Date:10/06/26
The score is held down primarily by very weak financial performance (zero/contracting revenue, persistent large losses, and sustained negative free cash flow with elevated funding risk) and bearish technicals (price below all key moving averages with negative MACD and very low RSI/Stoch). Valuation does not provide meaningful support given the negative P/E and lack of dividend data.
Positive Factors
Specialized immuno-oncology pipeline
A focused immuno-oncology strategy gives Imugene a clear scientific and commercial direction. Advancing multiple candidates through development can create meaningful future optionality if clinical programs demonstrate efficacy, while specialization may support expertise and differentiation in a large unmet-need area.
Negative Factors
No sustainable product revenue
The absence of consistent product revenue means Imugene is not currently funding operations through recurring commercial sales. With revenue falling to zero in 2026, financial performance remains dependent on advancing development assets and securing external capital rather than demonstrating a self-sustaining operating model.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized immuno-oncology pipeline
A focused immuno-oncology strategy gives Imugene a clear scientific and commercial direction. Advancing multiple candidates through development can create meaningful future optionality if clinical programs demonstrate efficacy, while specialization may support expertise and differentiation in a large unmet-need area.
Read all positive factors
Imugene (IMU) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$19.78M
Dividend YieldN/A
Average Volume (3M)3.66M
Price to Earnings (P/E)―
Beta (1Y)2.42
Revenue GrowthN/A
EPS Growth-2.15%
CountryAU
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.32
Shares Outstanding549,574,700
10 Day Avg. Volume3,257,193
30 Day Avg. Volume3,656,209
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.16
Price to Sales (P/S)0.00
P/FCF Ratio-0.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)N/A
Imugene Business Overview & Revenue Model
Company Description
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogenei...
How the Company Makes Money
Imugene does not have widely disclosed, consistent product-revenue streams from marketed therapies; as a clinical-stage biotechnology company, its operations have typically been funded primarily through external financing rather than recurring sal...
Imugene Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 4.40M | 4.97M | 11.78M | 12.97M |
| Gross Profit | -6.84M | 4.40M | 4.97M | 9.57M | 10.56M |
| EBITDA | -68.11M | -66.68M | -147.98M | -47.43M | -48.06M |
| Net Income | -105.34M | -69.02M | -149.68M | -37.91M | -37.87M |
Balance Sheet | |||||
| Total Assets | 23.03M | 83.59M | 151.40M | 197.06M | 147.61M |
| Cash, Cash Equivalents and Short-Term Investments | 2.63M | 21.94M | 94.54M | 153.15M | 99.89M |
| Total Debt | 6.30M | 10.65M | 2.19M | 553.47K | 673.43K |
| Total Liabilities | 14.02M | 38.56M | 33.14M | 7.44M | 8.90M |
| Stockholders Equity | 9.01M | 45.03M | 118.25M | 189.63M | 138.70M |
Cash Flow | |||||
| Free Cash Flow | -44.85M | -90.03M | -108.80M | -29.78M | -30.93M |
| Operating Cash Flow | -44.85M | -75.57M | -101.73M | -29.78M | -30.67M |
| Investing Cash Flow | -4.35M | -12.70M | -7.25M | 9.63K | -414.16K |
| Financing Cash Flow | 29.99M | 17.37M | 49.43M | 82.98M | 101.35M |
Imugene Technical Analysis
Negative
0.07
Price Trends
0.05
Negative
0.07
Negative
0.13
Negative
Market Momentum
>-0.01
Negative
37.41
Neutral
58.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMU, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.05, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 37.41 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IMU.
Imugene Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$4.35B | 93.09 | 7.11% | ― | 26.66% | 179.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$32.43M | -0.41 | -98.86% | ― | ― | -27.73% | |
44 Neutral | AU$61.77M | -7.83 | -44.93% | ― | ― | 25.27% | |
42 Neutral | AU$578.28M | -5.47 | -51.15% | ― | ― | -44.83% | |
42 Neutral | AU$15.05M | -3.20 | 186.62% | ― | ― | 10.18% | |
41 Neutral | AU$19.78M | -0.11 | -414.10% | ― | ― | -2.15% |
* Healthcare Sector Average
AU:IMU
Imugene
0.04
-0.35
-90.91%
AU:IMM
Immutep Ltd
0.02
-0.28
-92.00%
AU:PTX
Prescient Therapeutics Limited
0.05
<0.01
6.12%
AU:TLX
Telix Pharmaceuticals
13.06
-3.11
-19.23%
AU:NOX
Noxopharm Ltd.
0.05
-0.05
-48.96%
AU:CU6
Clarity Pharmaceuticals Ltd.
1.57
-3.05
-66.05%
Imugene Corporate Events
Imugene posts strong new responses in Phase 1b azer-cel trial for B-cell malignancies
Oct 19, 2026
Imugene has reported new efficacy data from its ongoing Phase 1b basket trial of its CAR T candidate azer-cel in B-cell malignancies, including a complete response in a CAR T-naïve marginal zone lymphoma patient and a partial response in a Ri...
Imugene Seeks ASX Quotation for Additional Ordinary Shares
Oct 14, 2026
Imugene Limited has applied for quotation on the ASX of 670,719 ordinary fully paid shares, to be issued on August 3, 2026. The new securities arise from the exercise of options or conversion of other instruments, modestly expanding the company...
Imugene Sets 2026 AGM, Flags Governance and Capital Management Resolutions
Oct 9, 2026
Imugene Limited has called its 2026 Annual General Meeting for 11 November in Sydney and online, outlining a broad agenda that includes adopting the remuneration report, re-electing and electing directors, and seeking approval for an employee shar...
Imugene reshapes leadership as it sharpens focus on azer-cel CAR T program
Oct 6, 2026
Imugene has appointed physician-scientist Dr John Le Gall as Chief Medical Officer, effective immediately, as it restructures its leadership to align with its focus on azer-cel, its allogeneic CD19 CAR T cell therapy. Former CMO Dr John Byon will ...
Imugene Posts Strong Early Responses in Azer-cel BTKi Combo Trial
Oct 4, 2026
Imugene has reported new efficacy data from Cohort 3 of its Phase 1b basket study of azer-cel combined with a BTK inhibitor in patients whose disease has progressed on prior BTKi therapy. Four additional patients reached their Day 28 assessment, w...
Imugene Director’s Options Expire, Adjusting Equity Mix Without New Dilution
Oct 1, 2026
Imugene Limited reported a change in director Jakob Dupont’s interests, disclosing that 50,001 options previously held under the company’s Employee Share Option Plan have expired without being exercised. Following this expiry, Dupont&#...
Imugene Seeks ASX Quotation for 15.8 Million New Shares
Sep 8, 2026
Imugene Limited has applied for quotation of 15,813,253 new ordinary fully paid shares on the ASX, expanding its listed securities base under the code IMU. The issuance, dated 8 September 2026, reflects the company’s ongoing use of equity ma...
Imugene Issues 43.4 Million New Shares Under Capital Raising
Sep 1, 2026
Imugene Limited has issued 43,368,423 fully paid ordinary shares at $0.095 each under a previously announced placement, with the new securities listed under ASX code IMU and issued on 25 August and 1 September 2026. The company confirmed the share...
Imugene seeks ASX quotation for 15.8 million new shares
Sep 1, 2026
Imugene Limited has applied to the ASX for quotation of 15,789,474 new ordinary fully paid shares, with the securities to be issued and quoted on 1 September 2026. The new shares form part of previously announced transactions and will increase the...
Imugene Director’s Options Lapse Without Exercise
Sep 1, 2026
Imugene Limited has disclosed a change in the interests of director Kim Drapkin, noting the expiry of 3,502 options exercisable at $4.012 on 31 August 2026 without conversion or exercise. Following the expiry, Drapkin’s holdings remain at 40...
Imugene Posts Wider Loss and Sharp Fall in Net Tangible Assets
Aug 28, 2026
Imugene Limited reported audited results for the year ended 30 June 2026 showing no dividends declared or paid, consistent with the previous financial year. The company also confirmed there were no changes in controlled entities, no associates or ...
Imugene Restructures Convertible Notes and Raises Capital to Back Cancer Trials
Aug 27, 2026
Imugene has entered into an amended subscription agreement with an affiliate of Heights Capital Management, linked to Susquehanna International Group, to issue new convertible notes and warrants. The transaction restructures $2.1 million of existi...
Imugene Issues New Warrants and Convertible Notes to Bolster Funding
Aug 26, 2026
Imugene Limited has notified the market of the issue of new unquoted securities, including 25,301,205 warrants expiring in August 2031 and 4,200 convertible notes expiring in January 2030, both dated 21 August 2026. The move indicates the company ...
Imugene Cancels 4,200 Convertible Notes Under Capital Management Move
Aug 26, 2026
Imugene Limited has reported the cessation of 4,200 convertible notes, identified under ASX security code IMUAAR. The notes were cancelled by mutual agreement between the company and the holder, effective 21 August 2026.The cancellation slightly r...
Imugene Seeks ASX Quotation for 27.6 Million New Shares
Aug 26, 2026
Imugene Limited has applied for quotation of 27,578,949 ordinary fully paid shares on the ASX, with an issue date of August 25, 2026. The new securities are tied to previously announced transactions, indicating a follow-through on capital-raising ...
Imugene Restructures Convertible Notes to Boost Financial Flexibility
Aug 21, 2026
Imugene Limited has renegotiated the terms of its existing convertible notes with CVI Investments, Inc., redeeming A$2.1 million of the notes and replacing them with new senior, unsecured, zero-coupon convertible notes. The remaining existing note...
Imugene shareholders back capital-raising resolutions at extraordinary meeting
Aug 19, 2026
Imugene Limited has confirmed that all resolutions put to shareholders at its Extraordinary General Meeting on 19 August 2026 in Sydney were passed by poll. The approved resolutions include ratifying a prior tranche of placement shares and authori...
Imugene doubles down on azer-cel as leadership shifts and fresh capital backs trial push
Aug 9, 2026
Imugene has reaffirmed its strategic focus on advancing its lead CAR T candidate azer-cel through clinical development, despite a recent leadership change that saw long-serving chief executive Leslie Chong step down for personal reasons. During th...
Imugene’s Deep Out-of-the-Money Options Set to Expire Without Underwriting
Aug 5, 2026
Imugene has notified investors that 21,698,915 listed options trading under ASX code IMUOE, each exercisable at $4.012, will expire unexercised if not paid by 5pm AEST on 31 August 2026. Official quotation of these options will cease on 25 August ...
Imugene Discloses Final Director Interest as Leslie Chong Exits Board
Jul 31, 2026
Imugene Limited has notified the ASX that chief executive and managing director Leslie Chong ceased to be a director on 27 July 2026, triggering a formal disclosure of her final interests in the company’s securities. The filing details Chong...
Imugene Adjusts Capital Structure as Performance Rights Lapse
Jul 31, 2026
Imugene Limited has disclosed the lapse of 847,722 performance rights awards, recorded under ASX code IMUAAO, after the conditions attached to these rights were not met or became incapable of being satisfied. The cessation was effective on 27 July...
Imugene Advances Azer-cel Program and Bolsters Balance Sheet With Fresh Capital
Jul 30, 2026
Imugene reported strong clinical progress for its lead cell therapy, azer-cel, during the June quarter, including complete and partial responses in a Phase 1b cohort combining the CAR-T with BTK inhibitors, a drug class with global sales above US$...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.